Dr Reddys Laboratories Ltd Valuation Shifts to Fair Amidst Sector Comparisons

Valuation Metrics: From Attractive to Fair

As of 14 May 2026, Dr Reddys Laboratories Ltd trades at a price of ₹1,265.10, slightly down by 0.39% from the previous close of ₹1,270.10. The stock’s 52-week range spans from ₹1,143.05 to ₹1,377.95, indicating a relatively stable price band over the past year. However, the recent shift in valuation grade from attractive to fair reflects a recalibration of investor expectations amid evolving market conditions.

The company’s current P/E ratio stands at 25.33, a figure that, while moderate, is higher than what was previously considered attractive. This contrasts with some of its peers in the Pharmaceuticals & Biotechnology sector, such as Sun Pharmaceutical Industries, which is deemed expensive with a P/E of 36.05, and Divi’s Laboratories, classified as very expensive at a P/E of 71.12. Torrent Pharmaceuticals also falls into the very expensive category with a P/E of 63.44. Cipla, meanwhile, remains attractive with a P/E of 26.29, marginally above Dr Reddys but still favourably positioned.

The price-to-book value ratio for Dr Reddys is currently 2.80, which aligns with the fair valuation grade. This metric suggests that the stock is trading at nearly three times its book value, a level that investors perceive as reasonable given the company’s asset base and earnings potential. The enterprise value to EBITDA ratio of 16.56 further supports this assessment, indicating a balanced valuation relative to earnings before interest, tax, depreciation, and amortisation.

Comparative Analysis with Sector Peers

When juxtaposed with its sector peers, Dr Reddys’ valuation appears more moderate. Sun Pharma’s EV/EBITDA ratio of 23.73 and Divi’s Lab’s 52.18 highlight the premium investors are willing to pay for companies with stronger growth prospects or market dominance. Torrent Pharma’s EV/EBITDA of 35.62 further emphasises this trend of elevated valuations within the sector.

Dr Reddys’ PEG ratio remains at 0.00, which may indicate a lack of consensus or a neutral stance on growth expectations relative to earnings. This contrasts sharply with Sun Pharma’s PEG of 12.23 and Divi’s Lab’s 3.15, both signalling high growth premiums embedded in their valuations. Cipla’s PEG ratio is also 0.00, suggesting a similar growth outlook to Dr Reddys.

Financial Performance and Return Metrics

Dr Reddys Laboratories’ return on capital employed (ROCE) and return on equity (ROE) stand at 11.43% and 11.07% respectively, reflecting a stable but unspectacular profitability profile. These figures suggest the company is generating reasonable returns on its investments and shareholder equity, though not at levels that might justify a premium valuation.

Dividend yield remains modest at 0.63%, which may be less attractive to income-focused investors but consistent with the company’s reinvestment strategy in research and development, a critical factor in the pharmaceuticals sector.

Examining stock returns relative to the benchmark Sensex reveals a mixed picture. Over the past week, Dr Reddys declined by 3.46%, slightly outperforming the Sensex’s 4.30% drop. Over one month, the stock gained 2.42%, contrasting with the Sensex’s 2.91% loss. Year-to-date, Dr Reddys is marginally down by 0.47%, outperforming the Sensex’s 12.45% decline. Over longer horizons, the stock has delivered robust returns, with a 3-year gain of 41.65% versus the Sensex’s 20.28%, and a 10-year return of 117.21% compared to the Sensex’s 192.70%. However, the 5-year return of 19.30% trails the Sensex’s 53.23%, indicating some periods of underperformance.

Market Capitalisation and Grade Revision

Dr Reddys Laboratories is classified as a large-cap stock, a status that typically confers greater stability and liquidity. Despite this, the company’s Mojo Score has been downgraded from Buy to Hold as of 4 May 2026, with a current score of 51.0. This downgrade reflects the shift in valuation grade from attractive to fair and suggests a more cautious stance among analysts and investors.

The downgrade is likely influenced by the stock’s valuation metrics relative to its historical averages and peer group, as well as broader market conditions impacting the Pharmaceuticals & Biotechnology sector. Investors may be factoring in increased competition, regulatory challenges, or slower growth prospects, which temper enthusiasm despite the company’s solid fundamentals.

Implications for Investors

The transition of Dr Reddys Laboratories’ valuation from attractive to fair signals a more balanced risk-reward profile. While the stock remains competitively priced relative to some expensive peers, the absence of a strong growth premium and the recent downgrade to Hold suggest investors should exercise caution.

Investors seeking exposure to the Pharmaceuticals & Biotechnology sector may find Dr Reddys suitable for a core portfolio holding, given its large-cap status, stable returns, and reasonable valuation. However, those looking for higher growth or more aggressive appreciation might consider alternatives with stronger momentum or more compelling valuation metrics.

It is also important to monitor the company’s operational performance, regulatory developments, and sector dynamics, which could influence future valuation adjustments. The current fair valuation grade implies limited upside from a price perspective, but also reduced downside risk compared to more richly valued peers.

Historical Valuation Context

Historically, Dr Reddys Laboratories has traded at lower P/E multiples during periods of market stress or sector headwinds, often below 20 times earnings. The current P/E of 25.33 represents a moderate premium to these historical lows but remains well below the valuations of some sector leaders. This suggests that while the stock is no longer a bargain, it is not excessively overvalued either.

The price-to-book ratio of 2.80 is consistent with the company’s asset quality and earnings power, reflecting investor willingness to pay a premium for intangible assets such as intellectual property and brand value. The EV/EBITDA multiple of 16.56 also aligns with mid-tier valuations within the sector, reinforcing the fair valuation assessment.

Conclusion

Dr Reddys Laboratories Ltd’s recent valuation shift from attractive to fair, accompanied by a downgrade in its Mojo Grade from Buy to Hold, underscores a more cautious market outlook. While the company maintains solid fundamentals and competitive positioning within the Pharmaceuticals & Biotechnology sector, its valuation metrics suggest limited near-term upside relative to peers.

Investors should weigh the company’s stable returns and large-cap status against the tempered growth expectations and sector challenges. For those seeking balanced exposure with moderate risk, Dr Reddys remains a viable option, but it may be prudent to explore alternative stocks with stronger momentum or more compelling valuations for enhanced portfolio performance.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →